

The National Academies of
SCIENCES • ENGINEERING • MEDICINE
HEALTH AND MEDICINE DIVISION
BOARD ON HEALTH SCIENCES POLICY

CLINICAL UTILITY OF TREATING PATIENTS WITH COMPOUNDED
"BIOIDENTICAL HORMONE REPLACEMENT THERAPY"

Open Session Meeting Agenda

Tuesday, November 12, 2019
Keck Center of the National Academies
500 Fifth Street, NW
Washington, D.C. 20001
Room 208

12:45 p.m. **Doors Open**

1:00 p.m. **Introductions**

LEIGH MILES JACKSON
Study Director, Board on Health Sciences Policy
Health and Medicine Division

DONALD MATTISON, MD
Committee Chair

RUTH PARKER, MD
Committee Vice-Chair

SESSION I National Perspectives on the Behalf of Compounding Professionals

1:05 p.m. **Perspectives from Professional Associations and Organizations**

Thomas Menighan, BSPharm, MBA, ScD (Hon), FAPhA
Executive Vice President and CEO
American Pharmacists Association

Ronna B. Hauser, PharmD
Vice President, Policy & Government Affairs Operations
National Community Pharmacist Association

1:30 p.m. **Q&A and Discussion (moderated by committee members)**

SESSION II Provider Education and Medical Care

1:45 pm **Perspectives from Providers**

Session Objectives:

- Collect perspectives on the clinical utility, safety, and effectiveness of cBHRT products.
- Review trends in the formulations and use of cBHRT and how decisions are made, related to cBHRT formulations.
- Discuss the professional education, training, and guidance for clinicians in the area of compounded products and their use.

Gary S. Donovan, M.D., FACOG

Founder

BioTE Medical, LLC

Pamela Smith, M.D., MPH, MS

Founder and Director

Center for Personalized Medicine

2:15 p.m. **Q&A and Discussion (moderated by committee members)**

2:45 p.m. **Break**

SESSION III **Pharmaceutical Sciences and Compounding Pharmacists**

3:00 p.m. **Perspectives from Compounding Pharmacists**

Session Objectives:

- Collect perspectives on the clinical utility, safety, and effectiveness of cBHRT products.
- Review trends in the formulations of cBHRT and how decisions are made, related to cBHRT formulations.
- Discuss the professional education and training in the formulation science of sterile and non-sterile compounding.
- To discuss formulation practices and quality control procedures.

Peter Koshland, PharmD

CEO

Koshland Pharmacy

Gina Besteman, R.Ph

Director of Compounding and Dispensing

Women's International Pharmacy

3:30 p.m. **Q&A and Discussion (moderated by committee members)**

4:00 p.m. **Public Comments**

4:30 p.m. **ADJOURN**